Characterization of two independent, exposure-time dependent paclitaxel-resistant human ovarian carcinoma cell lines Authors
Received: 09 September 2010 Accepted: 28 September 2010 DOI:
Cite this article as: Nakajima, K., Isonishi, S., Saito, M. et al. Hum Cell (2010) 23: 156. doi:10.1111/j.1749-0774.2010.00098.x
This experiment was conducted to address the question of whether acquired paclitaxel resistance is dependent upon whether it is given as a single brief exposure or as a long-term exposure. PX2 and PX24 were established from 2008 human ovarian cancer cells by 2-h single exposure or 24-h continuous exposure to paclitaxel. PX2 acquired paclitaxel resistance faster than PX24 by twofold. Drug resistant pattern was exposure-time dependent. In 2-h exposure, PX2 showed 53.86 ± 4.96 (mean ± standard deviation [SD]) fold paclitaxel resistance while PX24 showed 9.51 ± 1.01 fold resistance (
P = 0.002). In 24-h exposure, PX2 showed 2.31 ± 0.3 fold paclitaxel resistance while PX24 showed 28.1 7 ± 0.98 fold resistance ( P = 0.040). PX2 and PX24 acquired cross-resistance to docetaxel and SN38 and the resistance degrees were significantly higher in PX2 than PX24. They displayed approximately twofold cisplatin collateral sensitivity. PX24 also displayed sensitivity to other platinum drugs, oxaliplatin and ZD0473, whereas PX2 acquired significant resistance to both of them. Although differential tubulin-isotype expressions were noted among 2008, PX2 and PX24, they were not significant. In electron microscopy, prominent, densely stained lysosomes were observed more in the resistant cells than 2008. Two independent, exposure-time dependent paclitaxel-resistant human ovarian carcinoma cell lines were established. Understanding the characteristics of the differential resistance pattern could be clinically beneficial for the selection of second line chemotherapy for relapsed ovarian cancer.
ovarian carcinoma cells
Seidman AD, Hochhauser D, Gollub M
. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
J Clin Oncol
Armstrong DK, Bundy B, Wenzel L
. for the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
N Engl J Med
Katsumata N, Yasuda M, Takahashi F
. for the Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
Rischin D, Webster LK, Millward MJ
. Cremophor pharmaeokinetics in patients receiving 3-, 6-, and 24-h infusions of paclitaxel.
J Natl Cancer Inst
Deny WB, Wilson L, Jordan MA. Substoichiometric binding of taxol suppresses microtubule dynamics.
Di Saida PJ, Sinkovics JG, Rutledge FN. Cell-mediated immunity to human malignant cells.
Am J Obstet Gynecol 1972; 114: 979–89.
Gianni L, Kearns CM, Giani A
. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.
J Clin Oncol
Huizing MT, Keung ACF, Hilde Rosing H
. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.
J Clin Oncol
Hill AV. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves.
J Physiol 1910; 40: iv-vii.
Isonishi S, Saitou M, Saitou M, Yasuda M, Tanaka T. Differential regulation of the cytotoxicity activity of paclitaxel by orobol and platelet derived growth factor in human ovarian carcinoma cells.
Ranganathan S, Dexter DW, Benetatos CA, Chapman AE, Tew KD, Hudes GR. Increase of beta (III)- and beta (IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance.
Kavallaris M, Kuo DY-S, Burkhart CA
. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes.
J Clin Invest
Mithieux G, Audebet C, Rousset B. Association of purified thyroid lysosomes to reconstituted microtubules.
Biochim Biophys Acta
Zhan Z, Scala S, Monks A, Hose C, Bates S, Fojo T. Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration.
Cancer Chemother Pharmacol
Stewart DJ, Chiritescu G, Dahrouge S, Banerjee S, Tomiak EM. Chemotherapy dose-response relationships in non-small cell lung cancer and implied resistance mechanisms.
Cancer Treat Rev
Roy SN, Horwitz SB. A phosphoglycoprotein associated with taxol resistance in J774.2 cells.
Gore ME, Atkinson RJ, Thomas H
. A phase II trial of ZD0473 in platinum-pretreated ovarian cancer.
Eur J Cancer
Fracasso PM, Blessing JA, Morgan MA, Sood AK, Hoffman JS. Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a Gynecologic Oncology Group study.
J Clin Oncol
Brewer CA, Blessing JA, Nagourney RA, Morgan M, Hanjani P. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group.
Rose PG, Blessing JA, Ball HG
. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.
Cabral FR, Brady RC, Schibler MJ. A mechanism of cellular resistance to drugs that interfere with microtubule assembly.
Ann NY Acad Sci
Rahman YE. Electron microscopy of lysosome-rich fractions from rat thymus isolated by density-gradient centrifugation before and after whole-body X-irradiation.
J Cell Biol
CrossRef PubMed Copyright information
© Society and Springer Japan 2010